Health Headlines for Tuesday, October 4

Fidelis Care New York is expanding, hiring in Rochester

Democrat and Chronicle

A major health insurance provider in New York is expanding in Rochester and looking to grow its staff.

Read Full Article


Maryland’s ACA health co-op will switch to for-profit to save itself

Washington Post

Evergreen Health, Maryland’s version of the innovative nonprofit insurers created under the Affordable Care Act, decided Monday to become a for-profit company to avoid the possibility of a shutdown, according to its chief executive.

Read Full Article


Drugmakers Point Finger at Middlemen for Rising Drug Prices

Wall Street Journal

As U.S. drug prices rise, drugmakers are playing down their role, instead heaping blame on the middlemen who help determine how medicines are priced.

Read Full Article


3 Who Studied Unusual States of Matter Win Nobel Prize in Physics

New York Times

David J. Thouless, F. Duncan M. Haldane and J. Michael Kosterlitz were awarded the Nobel Prize in Physics on Tuesday for discoveries in condensed-matter physics that have transformed the understanding of matter that assumes strange shapes.

Read Full Article


How To Boost Competition In Obamacare

Forbes

When the Medicare Modernization Act created a new drug benefit and the Medicare Advantage programs, there were literally thousands of new health plans that were formed to offer these benefits.

Read Full Article


The 4 Traits That Put Kids at Risk for Addiction

New York Times

Drug education is the only part of the middle school curriculum I remember — perhaps because it backfired so spectacularly.

Read Full Article


Drinks, dinners, junkets and jobs: how the insurance industry courts state commissioners

The Center for Public Integrity

When the Arkansas insurance commissioner weighed the merits of a hospital’s billing complaint against United Healthcare, her interactions with one of the nation’s largest health insurers extended far beyond her department’s hearing room.

Read Full Article


Valeant’s Stock Becomes (Relatively) Quiet After Wild Year

Bloomberg

After a yearlong, up-and-down ride, shares of Valeant Pharmaceuticals International Inc. are enjoying a period of relative calm.

Read Full Article